2025-10-30 - Analysis Report
Okay, here's an analysis of TG Therapeutics (TGTX) based on the data you provided, formatted as a report:

## TG Therapeutics (TGTX) Stock Analysis

**Company Overview:** TG Therapeutics Inc. is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.

### 1. Performance vs. S&P 500 (VOO)

*   **TGTX Cumulative Return:** 83.22%
*   **VOO Cumulative Return:** 104.04%
*   **Absolute Divergence:** -13.6
*   **Relative Divergence:** 21.0

**Analysis:** TGTX has underperformed the S&P 500 (VOO) over the analyzed period.  The absolute divergence shows TGTX lagging VOO by 13.6 percentage points in cumulative return. The relative divergence of 21.0 indicates that TGTX's performance is in the lower quartile of its historical divergence range compared to VOO.

#### Alpha, Beta Analysis Table

| Year       | CAGR    | MDD     | Alpha   | Beta  | Cap(B) |
|------------|---------|---------|---------|-------|--------|
| 2015-2017  | -5.0%   | 73.5%   | -33.0%  | -0.0  | 1.3    |
| 2016-2018  | -12.0%  | 73.5%   | -27.0%  | -0.0  | 0.7    |
| 2017-2019  | 74.0%   | 74.1%   | 52.0%   | 0.0   | 1.8    |
| 2018-2020  | 316.0%  | 74.1%   | 293.0%  | 0.1   | 8.2    |
| 2019-2021  | 124.0%  | 74.1%   | 78.0%   | 0.3   | 3.0    |
| 2020-2022  | -71.0%  | 77.8%   | -71.0%  | -0.0  | 1.9    |
| 2021-2023  | -284.0% | 77.8%   | -285.0% | -1.1  | 2.7    |
| 2022-2024  | 56.0%   | 77.8%   | 36.0%   | -1.0  | 4.8    |
| 2023-2025  | 84.0%   | 80.6%   | 15.0%   | -0.1  | 5.5    |

**Analysis:**

*   **CAGR:** The Compounded Annual Growth Rate shows significant volatility in TGTX's performance, ranging from substantial losses (-284%) to impressive gains (316%).
*   **MDD:**  The Maximum Drawdown is consistently high, indicating significant risk.
*   **Alpha:** Alpha fluctuates significantly, suggesting periods of outperformance and underperformance relative to the market.
*   **Beta:** Beta values are generally low or negative, which suggests low correlation with the market; values close to zero imply the stock's returns are independent of market movements.
*   **Cap:** The market capitalization fluctuates between 0.7B to 8.2B.

### 2. Recent Price Action

*   **Current Price:** 34.86
*   **Previous Close:** 34.55
*   **Change:** 0.9%
*   **5-day Moving Average:** 33.993
*   **20-day Moving Average:** 34.997
*   **60-day Moving Average:** 32.1864

**Analysis:**  The stock is currently trading above its 5-day and 60-day moving averages but slightly below its 20-day moving average.  The recent price increase of 0.9% suggests short-term positive momentum.

### 3. Technical Indicators and Expected Return

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 44.28
*   **PPO:** -0.6538
*   **Hybrid Signal:** Cash_80%_Sell (80% of holdings)
*   **Recent (20-day) Relative Divergence Change:** 0.2 (Positive - Short-term Increase)
*   **Expected Return:** -102.7%

**Analysis:**

*   The MRI suggests a "High Investment Recommended" level, however this contradicts with Hybrid Signal.
*   The RSI of 44.28 is neutral.
*   The PPO is slightly negative, suggesting a minor downtrend.
*   The Hybrid Signal recommends selling 80% of holdings, highlighting potential risk.
*   The positive change in relative divergence indicates short-term upward momentum.
*   The extremely negative expected return of -102.7% suggests significant potential underperformance relative to the S&P 500 over a long-term investment horizon.  This is a strong warning sign.
*   The change of 0.9% from the previous close indicates a slight positive momentum and could be a reaction to the recent news or earnings expectations.

### 4. Recent News & Significant Events

*   **[2025-10-28]** TG Therapeutics Completes Enrollment in Phase 3 ENHANCE Trial for BRIUMVI. (Positive - trial progress)
*   **[2025-10-27]** TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q3 Release. (Positive - earnings outlook)
*   **[2025-10-04]** Institutional investors are TG Therapeutics, Inc.'s (NASDAQ:TGTX) biggest bettors and were rewarded after last week's US$176m market cap gain. (Positive - institutional support)
*   **[2025-10-04]** What TG Therapeutics (TGTX)'s Six-Year BRIUMVI Safety Data Means For Shareholders. (Positive - long-term safety data)

**Analysis:** Recent news is predominantly positive, focusing on clinical trial progress, positive earnings outlook, institutional investor confidence, and favorable long-term safety data for BRIUMVI.  This positive news flow could be a contributing factor to the recent price increase.

### 4-2. Analyst Opinions

*   **Consensus:** Buy (Mean: 1.78)
*   **Target Price:** 43.57 (Avg) / 60.00 (High) / 11.00 (Low)

**Analysis:** Analyst consensus is "Buy" with a significant upside potential based on the average target price.  However, the wide range between the high and low target prices indicates considerable uncertainty among analysts.

### 5. Recent Earnings Analysis

| 날짜       | EPS   | 매출      |
|------------|-------|-----------|
| 2025-08-08 | 0.19  | 0.14 B$   |
| 2025-05-09 | 0.03  | 0.12 B$   |
| 2024-11-07 | 0.03  | 0.08 B$   |
| 2024-08-09 | 0.05  | 0.07 B$   |
| 2025-08-08 | 0.05  | 0.07 B$   |

**Analysis:**  Recent EPS figures show positive results.  Revenue is also trending upwards.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-06-30 | $0.14B    | 86.58%        |
| 2025-03-31 | $0.12B    | 87.14%        |
| 2024-12-31 | $0.11B    | 85.77%        |
| 2024-09-30 | $0.08B    | 88.86%        |
| 2024-06-30 | $0.07B    | 88.70%        |

**Capital and Profitability:**

| Quarter    | Equity    | ROE   |
|------------|-----------|-------|
| 2025-06-30 | $0.28B    | 10.20% |
| 2025-03-31 | $0.24B    | 2.13%  |
| 2024-12-31 | $0.22B    | 10.49% |
| 2024-09-30 | $0.19B    | 2.02%  |
| 2024-06-30 | $0.18B    | 3.87%  |

**Analysis:** Revenue is showing consistent growth. Profit margins are exceptionally high, indicating strong operational efficiency.  Equity is increasing, suggesting healthy capital accumulation. ROE fluctuates, but recent values are reasonably good.

### 7. Summary and Conclusion

TG Therapeutics (TGTX) presents a mixed investment picture. While recent news flow, analyst ratings, earnings, revenue and profitability metrics are largely positive, the stock has underperformed the S&P 500, and the extremely negative expected return is a major cause for concern. The hybrid signal recommends reducing holdings (cash_80%_Sell), further reinforcing the idea of caution.

**Recommendation:** Given the high risk profile (MDD), underperformance relative to the market, and deeply negative expected return, a cautious approach is warranted. The positive news and analyst ratings suggest potential for future growth, but the risks are significant. It may be best to follow Hybrid Signal recommendations.
